Mechanisms of the HER3 Signaling Pathway

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected after the first quarter of 2025.

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.